English press releases

Kumulus Vape Launches on the Stock Exchange Tomorrow

Start of listing on Euronext Access™: Tuesday, May 28, 11.30 am CORBAS, France–(BUSINESS WIRE)– At 11.30 am this Tuesday, May 28 2019, shares in Kumulus...

Pioneering Project for Pharmaceutics – Vifor Pharma and the University of Basel are Jointly Establishing the World’s First Research Professorship for Nanopharmaceutical and Regulatory Science

Public-private partnership is intended to safeguard Switzerland’s competitive position in pharmaceutical technologies of the future ZURICH & BASEL, Switzerland–(BUSINESS WIRE)– Nanopharmaceutics promises ground-breaking innovation in...

New Investigational Clinical Data for Ipsen’s Oncology Products in 11 Solid Tumor Types to Be Presented at 2019 ASCO Annual Meeting

PARIS–(BUSINESS WIRE)– Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced that new data from clinical studies on investigational uses of cancer medicines cabozantinib (Cabometyx®),...

Kumulus Vape, the 100% Online E-Cigarette Specialist, Goes Public

First IPO of an e-cigarette company in Europe Listing by technical admission on Euronext Access™ on 28 May 2019 CORBAS, France–(BUSINESS WIRE)– Kumulus Vape (ISIN...

Network of 1,500 Stroke-Ready Clinics across Europe

The award-winning Angels Initiative delivers on its three-year goal to create a network of more than 1,500 stroke-ready clinics across Europe Since 2016, a total...

Dawex Raises €5 Million to Accelerate the Development of the Data Economy

Amadeus, Itochu Corporation, Bouygues Construction and Caisse des Dépôts invest to support innovation and data exchange technology PARIS–(BUSINESS WIRE)– Dawex, a leading data exchange technology...

Gilead Sciences to Present at the Jefferies 2019 Global Healthcare Conference on Wednesday, June 5

Webcast Available Through Gilead Corporate Website FOSTER CITY, Calif.–(BUSINESS WIRE)– Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Daniel O’Day, Gilead’s Chairman and Chief Executive...

Philip Morris International Strengthens Organizational Capabilities to Realize Its Vision for a Smoke-Free Future

New Leadership Positions Further Accelerate the Company’s Ability to Remain at the Forefront of Technology, Science and Consumer Centricity LAUSANNE, Switzerland–(BUSINESS WIRE)– Philip Morris International...

Elliott Statement on Uniper

LONDON–(BUSINESS WIRE)– In advance of Uniper SE’s (“Uniper” or the “Company”) Annual General Meeting tomorrow, Elliott Advisors (UK) Limited has decided to withdraw its proposed...

comforte AG Launches New Payments Industry Data Security Solution

WIESBADEN, Germany–(BUSINESS WIRE)– comforte AG today announced its Data Security Solution and Practice for the Payments Industry. The solution is making its debut at Card...

1 In 10 Banks Will Disappear over the Next 5 Years, According to A.T. Kearney

New ten-year study from A.T. Kearney predicts that 1 in 10 banks will disappear over the next 5 years as revenue from traditional banking models stagnate...

Arthur D. Little: Nord Stream 2 Provides Economic Benefits, Generates Innovation and Helps to Develop Contractors’ Businesses

Major infrastructure project has total economic benefit to EU of €9.9 billion LONDON–(BUSINESS WIRE)– The second part of a recent report from Arthur D. Little...

Sofinnova Partners Launch MD Start III Medtech Acceleration Fund at €48M

This is the third vehicle of the MD Start family, which was founded 10 years ago MD Start focuses on sourcing medtech innovations at their...

First patient treated in DIAMOND study to evaluate if Veltassa® (patiromer) improves outcomes by enabling long-term use of essential RAASi therapy

ZURICH–(BUSINESS WIRE)– Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190520005695/en/ Vifor Pharma today announced that treatment of the first patient...

Phase III study showed nintedanib slows the loss of pulmonary function in people living with systemic sclerosis associated ILD1

Results of pivotal Phase III SENSCIS® trial published today in the New England Journal of Medicine (NEJM) and presented at the American Thoracic Society Conference...